C4 THERAPEUTICS INC

Insider buying by C4 Therapeutics CFO signals confidence in the company’s biopharma pipeline and long‑term growth prospects, boosting investor optimism.

Discover why C4 Therapeutics’ chief medical officer is buying shares at zero cost after RSU vesting—insider confidence signals a biotech upside worth watching.

Insider buying at C4 Therapeutics shows confidence in its early‑stage pipeline, hinting at future commercial success and steady growth.

Insider sale by C4 Therapeutics’ chief medical officer shows routine portfolio rebalance, not a clear bet on the biotech’s near‑term outlook.